All In Biotech

Drug Trial Radar · NCT05390892

PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

PRECIDENTD: PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 6,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

6,000

Planned (sponsor's estimate)

Start

Sep 26, 2022

Primary completion

Mar 1, 2029

Study completion Mar 1, 2029

Sponsor

Lead sponsor
Brigham and Women's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Patient-Centered Outcomes Research Institute
First posted
May 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PRECIDENTD is a randomized, open label, pragmatic clinical trial designed to compare rates of the total number of cardiovascular, kidney, and death events among two alternative treatments for patients with type 2 diabetes (T2D) and either established atherosclerotic cardiovascular disease (ASCVD) or at high risk for ASCVD. To accomplish this objective, we will randomly assign 6,000 patients with established T2D and ASCVD or high-risk for ASCVD in a 1:1 allocation to sodium-glucose cotransporter-2 inhibitor (SGLT2i) or glucagon-like peptide-1 receptor agonists (GLP-1RA). Participants will be followed for the occurrence of the trial primary endpoint of the total (first and recurrent) number of episodes of myocardial infarction (MI), stroke, arterial revascularization, hospitalization for heart failure, development of end-stage kidney disease, kidney transplantation, and mortality, counting all events from randomization until end of study.

Conditions

  • Type2Diabetes
  • ASCVD

Interventions

  • SGLT2 inhibitorDrug

    Empagliflozin, dapagliflozin, or canagliflozin

  • GLP-1 receptor agonistDrug

    Dulaglutide, liraglutide, semaglutide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total (first and recurrent) cardiovascular, kidney, and death eventsTime frame: Through study completion, with an average follow up of approximately 3 years

Locations

36 sites in 1 country. Site status is shown where the registry gives one.

  • Longwood Research LLC

    Huntsville, Alabama · Recruiting

  • HonorHealth Research & Innovation Institute

    Scottsdale, Arizona · Recruiting

  • Eastside Clinical Research Associates

    Los Angeles, California · Recruiting

  • Kendall South Medical Center, Inc

    Miami, Florida · Recruiting

  • South Florida Research Solutions, LLC

    Pembroke Pines, Florida · Recruiting

  • NSC Research, Inc.

    Johns Creek, Georgia · Recruiting

  • Herman Clinical Research

    Suwanee, Georgia · Recruiting

  • University of Illinois Chicago

    Chicago, Illinois · Recruiting

  • Rush University Medical Center

    Hinsdale, Illinois · Recruiting

  • University of Iowa

    Iowa City, Iowa · Recruiting

  • University of Kansas Medical Center

    Fairway, Kansas · Recruiting

  • Johns Hopkins School of Medicine

    Baltimore, Maryland · Recruiting

  • MedStar Union Memorial Hospital

    Baltimore, Maryland · Recruiting

  • MedStar Health Research Institute - Good Samaritan Hospital

    Baltimore, Maryland · Recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

  • UMass Chan Medical School

    Worcester, Massachusetts · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Essentia Health

    Duluth, Minnesota · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • University of Missouri-Columbia

    Columbia, Missouri · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • Naomi Berrie Diabetes Center at New York Presbyterian-Columbia University

    New York, New York · Recruiting

  • Atrium Health Family Medicine Research Department

    Charlotte, North Carolina · Recruiting

  • Duke University Hospital

    Durham, North Carolina · Recruiting

  • Wooster Heart Group

    Wooster, Ohio · Recruiting

  • Oregon Health & Science University

    Portland, Oregon · Recruiting

  • Geisinger Medical Center

    Danville, Pennsylvania · Recruiting

  • Temple University Lewis Katz School of Medicine

    Philadelphia, Pennsylvania · Recruiting

  • Family Care Center at Kent Hospital

    Pawtucket, Rhode Island · Recruiting

  • Medical University of South Carolina

    Charleston, South Carolina · Recruiting

  • South Carolina Clinical Research, LLC

    Orangeburg, South Carolina · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • Premier Internal Medicine Associates of Houston

    Katy, Texas · Recruiting

  • North Dallas Research Associates

    McKinney, Texas · Recruiting

  • Kidney and Hypertension Specialists, PLLC

    Manassas, Virginia · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.